Form 4: Shattuck Labs CEO Boosts Stake in Private Placement

Shattuck Labs CEO Taylor Schreiber acquired 25,610 shares and warrants in a private placement, increasing his direct beneficial ownership.

Summary

• Shattuck Labs, Inc. CEO and Director Taylor Schreiber acquired 25,610 shares of common stock and accompanying warrants.
• The transaction occurred on August 25, 2025, as part of a private placement that closed on the same date.
• The combined price for each share and accompanying warrant was $0.8677.
• The warrants allow the purchase of up to an aggregate of 25,610 additional shares of common stock at an exercise price of $1.0846.
• Post-transaction, Mr. Schreiber directly owns 96,612 shares of common stock and 25,610 warrants.
• He also indirectly owns 2,610,750 shares of common stock through Houghton Capital Holdings, LLC.

Sentiment

Score: 7

Explanation: The CEO's direct participation in a private placement to acquire shares and warrants indicates strong insider confidence and a positive outlook on the company's future, particularly given the capital raise aspect for funding clinical development.

Positives

• CEO Taylor Schreiber increased his direct beneficial ownership in the company, signaling strong insider confidence.
• Shattuck Labs successfully completed a private placement, securing capital for its operations and clinical development.

Risks

• The exercisability of the acquired warrants is contingent upon the public announcement of Phase 1 clinical trial data for SL-325 and the design of planned Phase 2 trials, linking investment returns to clinical development outcomes and associated risks.

Future Outlook

The exercisability of the acquired warrants is contingent upon the public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s), indicating future milestones related to the company's drug development pipeline.

Industry Context

Insider participation in private placements is a common method for biotechnology companies to raise capital, especially for funding ongoing clinical trials. The structure of the warrants, tied to clinical trial data, is typical for early-stage biotech firms, linking investor returns to scientific progress and de-risking milestones.

Related Party Transactions

• CEO Taylor Schreiber, as an accredited investor, participated in a private placement with Shattuck Labs, Inc., acquiring shares and warrants.

Stakeholder Impact

• Shareholders: The insider buying by the CEO provides a positive signal of confidence, potentially influencing investor sentiment.
• Creditors: The capital raise from the private placement strengthens the company's financial position, potentially reducing credit risk.

Next Steps

• Public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety data.
• Public announcement of the design of planned Phase 2 clinical trial(s) for SL-325.

Key Dates

Recommendation

The CEO's direct participation in the private placement, acquiring additional shares and warrants, signals strong insider confidence in Shattuck Labs' future prospects and the value of its pipeline, particularly SL-325. This capital raise strengthens the company's financial position to advance clinical trials. While biotech investments carry inherent risks, this insider buying provides a positive signal for investors.

Keywords

Shattuck Labs, STTK, Insider Buying, Private Placement, Taylor Schreiber, Warrants, Biotechnology, Clinical Trials, SL-325